Investment Thesis
vTv Therapeutics faces critical fundamental deterioration with complete revenue collapse (-100% YoY to $0.00) and sustained operating losses (-$32.8M) despite a strong balance sheet. While $88.9M cash and minimal debt (0.02x leverage) provide near-term runway (~3.5 years at current burn), the absence of revenue generation combined with negative ROE/ROA (-41.9% / -30.0%) and -$25.3M operating cash burn indicates a broken business model requiring dramatic operational recovery or strategic restructuring.
Strengths
- Fortress balance sheet: $88.9M cash with only $1.3M long-term debt and 0.02x debt-to-equity ratio
- Strong liquidity position: 13.54x current ratio provides financial flexibility for operations and R&D
- Positive stockholders' equity of $64.4M creates buffer against balance sheet deterioration
Risks
- Complete revenue collapse: Zero revenue with -100% YoY decline indicates loss of primary revenue source or product failure
- Severe operating losses: -$32.8M operating income and -$27.0M net loss with negative ROE/ROA (-41.9%/-30.0%) show fundamental unprofitability
- Negative operating cash flow: -$25.3M FCF burn rate unsustainable long-term; at current rate, cash depleted in ~3.5 years without revenue recovery
- No clear revenue catalyst: Absence of sales combined with ongoing losses suggests business model failure or incomplete restructuring
Key Metrics to Watch
- Revenue regeneration timeline and magnitude from existing or new programs
- Quarterly operating cash burn rate trend (acceleration/deceleration)
- Cash runway remaining and covenant compliance with remaining liabilities
- Form 4 insider buying activity and management commentary on path to profitability
Financial Metrics
Revenue
0.0
Net Income
-27.0M
EPS (Diluted)
$0.00
Free Cash Flow
-25.3M
Total Assets
89.9M
Cash
88.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-41.9%
ROA
-30.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
13.54x
Quick Ratio
13.54x
Debt/Equity
0.02x
Debt/Assets
28.3%
Interest Coverage
-2,523.69x
Long-term Debt
1.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-18T22:39:24.004572 |
Data as of: 2025-12-31 |
Powered by Claude AI